MedTrace Logo

Partial Tear of Supraspinatus (SSP) and Treatment With Plasma Rich in Growth Factors (PRGF)

NCT01152658 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-01-29

No results posted yet for this study

Summary

The objective of this clinical trial is to evaluate the impact and symptomatic efficacy of platelets rich plasma (PRP \\ PRGF) in the treatment of partial tears of supraspinatus tendon of rotator cuff.

Speed of tendon healing of partial thickness tear of the supraspinatus tendon influenced by local injection of platelets rich plasma

Conditions

  • Partial Supraspinatus Tear

Interventions

BIOLOGICAL

PRGF

enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control in the ssp gap

OTHER

NACL

Nack 0.9 5 will be then injected to the control group group in sterile conditions under ultrasound control

Sponsors & Collaborators

  • Meir Medical Center

    lead OTHER

Principal Investigators

  • Ezequiel Palmanovich, MD · Meir Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-05-31
Completion
2012-06-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01152658 on ClinicalTrials.gov